- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Familial partial lipodystrophy type 2 may lead to diabetes , suggests study

Many people may have a dim view of their fat tissue, yet scientists have come to recognize adipose as a necessary and metabolically active organ, carrying out many vital functions within the body.
In the case of obesity, too much fat can contribute to conditions such as diabetes and heart disease. Intriguingly, for people with certain rare genetic and autoimmune disorders, such as familial partial lipodystrophy type 2 (FPLD2), the abnormal loss and distribution of adipose tissue can also lead to diabetes and metabolic disease.
This paradox had long vexed Elif Oral, M.D., a clinician and Professor in the Division of Metabolism, Endocrinology and Diabetes. She’s dedicated her research career to uncovering the underlying mechanism of pathological fat loss, to help patients with lipodystrophy syndromes.
With the generous help of patients with FPLD2, Oral along with Ormond MacDougald, Ph.D., Professor of Molecular & Integrative Physiology, graduate student researcher Jessica Maung, Ph.D., and their collaborative team have finally found some answers.
“A simple explanation is that all of the fat cells (adipocytes) have really catastrophic things happening in them,” said Maung. The team created a mouse model in which they inducibly knocked out the lamin A/C gene in adipocytes, which is mutated in patients with FPLD2.
The team observed in both animal models and in patient donor tissue that dramatic gene expression changes lead to the fat cells being unable to carry out their normal lipid handling and storage functions. In addition, the fat cells themselves and the immune cells within adipose tissue became pro-inflammatory. Finally, mitochondria inside the fat cells became dysfunctional.
Said Maung, “All of these effects come together to create this perfect environment for the tissue to be really unhealthy and eventually disappear.”
In the absence of healthy adipose tissue, the normal maintenance of lipids and release of metabolic hormones goes awry, leading to metabolic diseases like diabetes and fatty liver disease.
“This is really underscoring the importance of healthy fats in keeping metabolism intact and functional,” said Oral. People think of Type 2 diabetes as a disease of beta cells, but it’s actually a disease of fat cells, too.”
The team hopes that these insights will help identify future therapeutic targets, enable targeting of adipose tissue to prevent it from disappearing, and correct metabolic dysfunction in this disease.
“I think this work is an outstanding example of a collaboration between a translational clinical researcher and a basic science physiologist,” said MacDougald. “We also can’t overstate the importance of the patient population and their involvement in developing therapies and their dedication to understanding their disease.”
Reference:
Altered lipid metabolism and inflammatory programs associated with adipocyte loss in familial partial lipodystrophy 2,” The Journal of Clinical Investigation, DOI:10.1172/JCI198387.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

